Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (21291)	4/23/1999 8:38:00 PM
From: DAVID	Read Replies (2) \| Respond to of 23519

DaiS, <<Because of low alprostadil content it could be marketed profitably at perhaps 25% or less of the cost of muse.>> Do you mean that the standard cost of current MUSE ($$$ amount Vivus records on its books to indicate the $$$ cost to manufacture the finished product) is 4 times as expensive as ALIBRA or that the patient price is 1/4 of the current MUSE price to the patient ? <<Alibra provides Vivus with excellent bargaining position for partner/buyout because Astra Janssen do not have alibra distribution rights!>> I guess I have been sleeping while I read these posts. This is new to me in the last weeks or so. I am rather astounded A & J have no distribution agreement in place. This is a key piece of information to further our hope that AZ becomes a domestic partner and continued outside the US partner. If A & J do not pick up the ALIBRA distribution agreement, they might just wash their hands of the whole ED mess. I can't imagine that to happen. DAVID